P=N/A, N=60, Not yet recruiting, Melbourne Health

P=N/A, N=1952, Not yet recruiting, Yonsei University

P=N/A, N=10000, Recruiting, JW Pharmaceutical

Knock down of SCD1 enhanced the percentage of dead cells in vehicle control treated cells but did not alter the abilities of drugs to kill tumor cells. Our data demonstrates that UM cells are killed by treatment with aramchol plus regorafenib plus metformin via enhanced autophagic flux and that this combination may have the potential to control UM tumors that have metastasized to the liver.

P=N/A, N=2560, Active, not recruiting, Daiichi Sankyo | Not yet recruiting --> Active, not recruiting

P1, N=32, Recruiting, Galmed Pharmaceuticals Ltd | Not yet recruiting --> Recruiting

Additionally, myeloid differentiation primary-response protein 88 (MYD88), TNF Receptor Associated Factor 6 (TRAF-6) and IL-6 were markedly reduced in the liver by EZE. Collectively, EZE may be a promising candidate in sepsis-related liver injury following further clinical studies.

P=N/A, N=6927, Completed, JW Pharmaceutical

P4, N=88, Active, not recruiting, JW Pharmaceutical

P=N/A, N=4400, Not yet recruiting, Yonsei University

Repurposed drugs such as flubendazole and the ezetimibe derivative L14-8, along with natural compounds including evodiamine and luteolin, demonstrate translational potential for ferroptosis induction. Collectively, ferroptosis represents a promising therapeutic vulnerability for precision treatment of advanced prostate cancer.

P=N/A, N=400, Active, not recruiting, Brigham and Women's Hospital | Trial completion date: Sep 2025 --> Jun 2026